findmyKOL
Clinical trialNCT05172258Active, not recruitingPhase 2Interventional

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

SponsorNational Cancer Institute (NCI)Enrollment52Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell Carcinoma+9 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope Comprehensive Cancer Center

    Duarte, California, United States

  • City of Hope at Irvine Lennar

    Irvine, California, United States

  • City of Hope Antelope Valley

    Lancaster, California, United States

  • Keck Medicine of Usc Koreatown

    Los Angeles, California, United States

  • Los Angeles General Medical Center

    Los Angeles, California, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Usc Norris Oncology/hematology-Newport Beach

    Newport Beach, California, United States

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, United States

  • Northwestern University

    Chicago, Illinois, United States

  • University of Kentucky/markey Cancer Center

    Lexington, Kentucky, United States

  • Nyu Langone Hospital - Long Island

    Mineola, New York, United States

  • Laura and Isaac Perlmutter Cancer Center at Nyu Langone

    New York, New York, United States

  • Nyp/weill Cornell Medical Center

    New York, New York, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, United States

  • University of Texas Medical Branch

    Galveston, Texas, United States

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Jul 2022
Primary completion
30 Jun 2027
Completion
30 Jun 2027
Last update posted
13 May 2026
Registered enrollment
52
Registry id
NCT05172258

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.